- Home
- QLYS vs GUTS Comparison
QLYS vs GUTS Comparison
Compare QLYS & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLYS
- GUTS
- Stock Information
- Founded
- QLYS 1999
- GUTS 2010
- Country
- QLYS United States
- GUTS United States
- Employees
- QLYS N/A
- GUTS N/A
- Industry
- QLYS Computer Software: Prepackaged Software
- GUTS
- Sector
- QLYS Technology
- GUTS
- Exchange
- QLYS Nasdaq
- GUTS NYSE
- Market Cap
- QLYS 5.7B
- GUTS 110.1M
- IPO Year
- QLYS 2012
- GUTS 2024
- Fundamental
- Price
- QLYS $140.73
- GUTS $1.79
- Analyst Decision
- QLYS Hold
- GUTS Buy
- Analyst Count
- QLYS 18
- GUTS 2
- Target Price
- QLYS $154.19
- GUTS $18.00
- AVG Volume (30 Days)
- QLYS 298.7K
- GUTS 292.2K
- Earning Date
- QLYS 02-05-2025
- GUTS 02-02-2025
- Dividend Yield
- QLYS N/A
- GUTS N/A
- EPS Growth
- QLYS 22.85
- GUTS N/A
- EPS
- QLYS 4.53
- GUTS N/A
- Revenue
- QLYS $592,950,000.00
- GUTS $97,000.00
- Revenue This Year
- QLYS $11.24
- GUTS N/A
- Revenue Next Year
- QLYS $7.62
- GUTS N/A
- P/E Ratio
- QLYS $31.07
- GUTS N/A
- Revenue Growth
- QLYS 9.66
- GUTS N/A
- 52 Week Low
- QLYS $119.17
- GUTS $1.74
- 52 Week High
- QLYS $206.25
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- QLYS 38.20
- GUTS 36.46
- Support Level
- QLYS $140.19
- GUTS $2.00
- Resistance Level
- QLYS $159.73
- GUTS $2.13
- Average True Range (ATR)
- QLYS 3.45
- GUTS 0.20
- MACD
- QLYS -2.42
- GUTS -0.05
- Stochastic Oscillator
- QLYS 2.76
- GUTS 4.76
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.